Literature DB >> 18550610

Interpretation of treatment changes in 6-minute walk distance in patients with COPD.

M A Puhan1, M J Mador, U Held, R Goldstein, G H Guyatt, H J Schünemann.   

Abstract

There is uncertainty about the interpretation of changes in the 6-min walk distance (6MWD) in chronic obstructive pulmonary disease (COPD) patients and whether the minimal important difference (MID) for this useful outcome measure exists. Data were used from nine trials enrolling a wide spectrum of COPD patients with 6MWD at baseline and follow-up and used to determine threshold values for important changes in 6MWD using three distribution-based methods. Anchor-based methods to determine a MID were also evaluated. Data were included of 460 COPD patients with a mean+/-sd forced expiratory volume in one second (FEV(1)) of 39.2+/-14.1% predicted and 6MWD of 361+/-112 m at baseline. Threshold values for important effects in 6MWD were between 29 and 42 m, respectively, using the empirical rule effect size and the standardised response mean. The threshold value was 35 m (95% confidence interval 30-42 m) based on the standard error of measurement. Correlations of 6MWD with patient-reported anchors were too low to provide meaningful MID estimates. 6-min walk distance should change by approximately 35 m for patients with moderate to severe chronic obstructive pulmonary disease in order to represent an important effect. This corresponds to a 10% change of baseline 6-min walk distance. The low correlations of 6-min walk distance with patient-reported anchors question whether a minimal important difference exists for the 6-min walk distance.

Entities:  

Mesh:

Year:  2008        PMID: 18550610     DOI: 10.1183/09031936.00140507

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  84 in total

1.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Milo A Puhan; Diana Lam; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

2.  Effect of Resveratrol on Walking Performance in Older People With Peripheral Artery Disease: The RESTORE Randomized Clinical Trial.

Authors:  Mary M McDermott; Christiaan Leeuwenburgh; Jack M Guralnik; Lu Tian; Robert Sufit; Lihui Zhao; Michael H Criqui; Melina R Kibbe; James H Stein; Donald Lloyd-Jones; Stephen D Anton; Tamar S Polonsky; Ying Gao; Rafael de Cabo; Luigi Ferrucci
Journal:  JAMA Cardiol       Date:  2017-08-01       Impact factor: 14.676

3.  Tai chi exercise for patients with chronic obstructive pulmonary disease: a pilot study.

Authors:  Gloria Y Yeh; David H Roberts; Peter M Wayne; Roger B Davis; Mary T Quilty; Russell S Phillips
Journal:  Respir Care       Date:  2010-11       Impact factor: 2.258

4.  Comparison of Effects of Endurance and Strength Training Programs in Patients with COPD.

Authors:  Michael J Berry; Katherine L Sheilds; Norman E Adair
Journal:  COPD       Date:  2018-04-16       Impact factor: 2.409

5.  Clinician's Commentary.

Authors:  Gail Dechman
Journal:  Physiother Can       Date:  2010-10-18       Impact factor: 1.037

Review 6.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 7.  Noninvasive positive pressure ventilation for chronic respiratory failure patients with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01

Review 8.  Impact of bronchodilator therapy on exercise tolerance in COPD.

Authors:  B Aguilaniu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-04-07

9.  Internet-based dyspnea self-management support for patients with chronic obstructive pulmonary disease.

Authors:  Huong Q Nguyen; DorAnne Donesky; Lynn F Reinke; Seth Wolpin; Lawrence Chyall; Joshua O Benditt; Steven M Paul; Virginia Carrieri-Kohlman
Journal:  J Pain Symptom Manage       Date:  2012-10-13       Impact factor: 3.612

Review 10.  Chronic obstructive pulmonary disease (COPD) evidentiary framework.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.